Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_assertion type Assertion NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_head.
- NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_assertion description "[In contrast to EBV(+) PTLD which expresses the immunodominant EBV latency III EBNA3A/B/C proteins, EBV(+) cHL is restricted to the subdominant EBNA1/LMP1/LMP2 proteins.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_provenance.
- NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_assertion evidence source_evidence_literature NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_provenance.
- NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_assertion SIO_000772 25731678 NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_provenance.
- NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_assertion wasDerivedFrom befree-2016 NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_provenance.
- NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_assertion wasGeneratedBy ECO_0000203 NP1267492.RALAZxwSL_CHTkFQgVYIxVeS94VpvGTe9EoUA37x6y8nI130_provenance.